Speech by the Chairman of Fujian Cosunter Pharmaceutical Co., Ltd.
Today, April 22, 2015, we are listed in Shenzhen Stock Exchange. Fujian Cosunter Pharmaceutical Co., Ltd., the first company in Ningde, Fujian listed in the said exchange, is a young modern pharmaceutical enterprise.
“The 9th List of Top 50 Enterprises with the Most Investment Value in China” is Revealed
In 2014, the venture capital industry entered a fierce competition and surged forward vigorously, as a result of the frequent release of good news in domestic and international capital markets, strong pickup of American capital market, gradual opening of gates to A-share, grand launch of the new three boards, and registration system injecting huge confidence into the market.
NCLD2014 Release Data of a 48-week Clinical Trial Using Enganding Indicating Clinical Equivalence to Imported Entecavir
On “The 9th National Conference of Liver Disease & The 3rd European Association for the Study of the Liver (EASL) Day”, Professor Ren Hong, Deputy Chairman of the Committee of the Chinese Society of Hepatology, CMA and President of the Second Affiliated Hospital of Chongqing Medical University initially announced the data from a 48-week phase-4 clinical trial using entecavir, showing the clinical equivalence of Cosunter Enganding - Entecavir Capsules to the imported entecavir.
CMACSI Data Indicate Clinical Equivalence of Lamivudine Tablets (Heganding) Manufactured by Cosunter to Imported Drugs
The 13th National Academic Conference for Infectious Diseases organized by the Chinese Society of Infectious Diseases, CMA was held successfully at Guangzhou Baiyun International Convention Center from June 13 to 16, 2014.